BioCentury | Mar 17, 2020
Finance

With strengthened balance sheet, Keros is latest biotech looking to test IPO market

...antibody domain. Keros’ ALK2 inhibitor KER-047 is Phase I testing to treat anemia resulting from hepcidin...
BioCentury | Jan 29, 2020
Company News

Management tracks: Century Therapeutics, Passage, Forbion, Bavarian, Disc, Biocartis, QuantuMDx and more

...NASDAQ:XLRN). Disc debuted in October with a $50 million series A and a pair of hepcidin...
...indications related to ineffective red blood cell production (see “Disc Medicine: Seeking Iron Balance via Hepcidin”...
BioCentury | Nov 26, 2019
Company News

Nov. 25 Company Quick Takes: FDA approves GBT's sickle cell therapy; plus ChemoCentryx, Astellas, La Jolla, Sorrento, Aquestive

...β thalassemia and said it will "reassess continued development" of the candidate. While the synthetic hepcidin...
BioCentury | Oct 30, 2019
Emerging Company Profile

Disc Medicine: Seeking Iron Balance via Hepcidin

...Disc debuted Tuesday with a $50 million series A round and a pair of hepcidin modulators...
...hepcidin axis that showed it was possible to intervene in diseases by modulating the hormone. “Hepcidin...
...from AbbVie. Inhibiting HFE2, another hepcidin regulator, is intended to treat diseases where up-regulation of hepcidin...
BioCentury | Mar 30, 2018
Clinical News

Protagonist discontinues Phase IIb of PTG-100 for UC

...The company’s remaining pipeline includes PTG-200, an oral IL-23 receptor antagonist, and PTG-300, an injectable hepcidin...
BioCentury | Mar 26, 2018
Clinical News

Protagonist shares halved on UC failure

...The company’s remaining pipeline includes PTG-200, an oral IL-23 receptor antagonist, and PTG-300, an injectable hepcidin...
BioCentury | Jun 8, 2017
Targets & Mechanisms

Pumping iron

...the space is patients with inflammation-induced anemia. During inflammation, high levels of the liver hormone hepcidin...
...L-aptamer hepcidin inhibitor in Phase II testing, while Lilly’s anti-hepcidin mAb LY2787106 and Pieris’ anticalin hepcidin...
...release from hepcidin-treated macrophages in vitro and plans to test it in animal models of hepcidin-related...
BioCentury | Mar 3, 2017
Company News

Pieris, Aska deal

...kidney disease in patients on hemodialysis, which is expected next half. PRS-080 is an anticalin hepcidin...
BioCentury | Nov 21, 2016
Product Development

AML Takes ASH

...the most common among the preclinical non-cancer abstracts. In addition to the usual suspects of hepcidin...
BioCentury | Nov 17, 2016
Product R&D

Hemorrhaging targets

...As expected, the top two targets appearing in the most preclinical hematology abstracts this year, hepcidin...
Items per page:
1 - 10 of 60